Conor Barry
Vice President, Global Head of Bioconjugate & Large Molecule R&D Piramal Pharma Solutions
Seminars
Wednesday 10th June 2026
Evaluating Phase & Product Appropriate Bioconjugate Development
12:00 pm
- Exploring the differing development approaches of ADCs across the preclinical to commercial spectrum
- Understanding how the bioconjugate landscape now encompasses a wide variety of modalities with differing mechanisms of action and molecular structures
- Exploring relevant examples of how the requirements for process and analytical development can vary between different conjugates
